USPTO serial 98962149
IVY BIOSCIENCES
Status 641Office Action
- Filing date
- Jan 14, 2025
- Status date
- Apr 28, 2026
- Registration date
- —
- Examiner
- HOLLAND, JAMI ELENA
Need help with IVY BIOSCIENCES?
CopyMark Law Group can help you respond to USPTO correspondence, keep a registration alive, or watch new filings against your mark.
What this means
The USPTO has issued an Office Action on this application. A response is typically required before the deadline, or the application can be abandoned.
Deadline: July 28th, 2026
Office Action issues
The USPTO has refused your application because your mark is too similar to existing registrations, you need to disclaim a descriptive word, and you must provide a valid physical business address.
Owner
Ivy Biosciences LLC
Nashville, TN, US
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical agents affecting metabolism; Pharmaceutical preparations for inducing erections; Pharmaceutical preparations for the treatment of hormonal disorders; Pharmaceutical preparations for treating diabetes; Pharmaceuticals for the treatment of erectile dysfunction; Pharmaceuticals, namely, inducers of erections; Anti-diabetic pharmaceuticals; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders | ACTIVE | — |
| 042 | Research and development in the field of biotechnology; Research in the field of human reproductive science; Biochemical research; Biochemical research and analysis; Biochemical research and development; Biological research; Biomedical research services; Biotechnology research; Medical research; Pharmaceutical research services; Providing medical research information in the field of pharmaceuticals; Providing scientific research information in the field of pharmaceuticals; Scientific research; Scientific research and development; Scientific research consulting | ACTIVE | — |
Prosecution history
| Date | Code | Event |
|---|---|---|
| Jul 27, 2026 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Jul 27, 2026 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Apr 28, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Apr 28, 2026 | GNRT | NON-FINAL ACTION E-MAILED |
| Apr 28, 2026 | CNRT | NON-FINAL ACTION WRITTEN |
| Apr 10, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Apr 10, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Apr 10, 2026 | ALIE | ASSIGNED TO LIE |
| Apr 7, 2026 | NREV | NOTICE OF REVIVAL - E-MAILED |
| Apr 7, 2026 | PETG | PETITION TO REVIVE-GRANTED |
| Mar 27, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Mar 27, 2026 | PROA | TEAS PETITION TO REVIVE RECEIVED |
| Jan 28, 2026 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
| Jan 28, 2026 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
| Sep 24, 2025 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED |
| Sep 24, 2025 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED |
| Jul 15, 2025 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Jul 15, 2025 | GNRT | NON-FINAL ACTION E-MAILED |
| Jul 15, 2025 | CNRT | NON-FINAL ACTION WRITTEN |
| Jun 24, 2025 | DOCK | ASSIGNED TO EXAMINER |
| Jun 13, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Jan 14, 2025 | NWAP | NEW APPLICATION ENTERED |